Want to see MRK full AI Analyst Report?
MRK Stock Chart & Stats
$156.45
$0.59(0.45%)
At close: 4:00 PM EDT
$156.45
$0.59(0.45%)
Day’s Range― - ―
52-Week Range$82.01 - $156.92
Previous CloseN/A
Volume6.15M
Average Volume (3M)9.48M
Market Cap
$365.88B
Enterprise Value$364.17B
Total Cash (Recent Filing)$7.14B
Total Debt (Recent Filing)$53.91B
Price to Earnings (P/E)117.7
Beta0.27
Next Earnings
Oct 29, 2026EPS Estimate
2.09Next Dividend Ex-DateN/A
Dividend Yield2.29%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,467,171,600
10 Day Avg. Volume9,290,867
30 Day Avg. Volume9,476,224
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.48
Enterprise Value/Gross Profit7.28
Enterprise Value/Ebitda26.15
Forecast
1Y Price Target
$159.76Price Target Upside2.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)2.65
Revenue Forecast (FY)$67.04B
Bulls Say, Bears Say
Bulls Say
Cash GenerationRobust and improving free cash flow gives Merck internally generated funds to support dividends, repurchases, debt service, and pipeline investment. Healthy cash conversion provides resilience when reported earnings fluctuate and strengthens the company’s ability to sustain strategic spending.
Commercial MomentumPositive quarterly growth and raised, narrowed guidance indicate that Merck’s core commercial platform remains capable of producing expansion despite a mature portfolio. Continued execution across multiple products can support more predictable revenue over the next several quarters.
Pipeline And DiversificationProgress across oncology, immunology, infectious disease, and other pipeline programs improves the prospect of replenishing future growth as existing products mature. Animal Health diversification further broadens revenue sources beyond human pharmaceuticals and reduces reliance on one therapeutic area.
Bears Say
Profitability DeclineThe sharp TTM profitability decline reduces earnings predictability and weakens returns on the company’s substantial capital base. If lower margins persist, Merck may have less flexibility to absorb development costs, fund acquisitions, or offset pressure from product-cycle changes.
Keytruda SC Patent RiskThe European injunction directly constrains commercialization of Keytruda’s subcutaneous formulation across several markets, limiting a route for administration-based lifecycle expansion. Although intravenous Keytruda remains available, the ruling creates ongoing regulatory and legal uncertainty around the SC opportunity.
Pipeline SetbackWithdrawal of the application delays potential access to a new oncology indication and demonstrates that not all late-stage assets will translate into near-term commercialization. Continued Phase 3 enrollment preserves optionality, but approval timing and development costs remain uncertain.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $82.01 and its highest was $156.92 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $365.88B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Aug 04, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.14.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 2.29%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.09.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,467,171,600 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 0.179%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$159.76 (2.12% Upside)
$159.76 (2.12% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 77%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 11.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.84%
12-Months-Change
Fundamentals
Return on Equity
6.60%
Trailing 12-Months
Asset Growth
10.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and scientific story: core revenue growth (Q2 +5%), several strong product performances (KEYTRUDA, WELIREG, WINREVAIR), meaningful vaccine and pneumococcal momentum, multiple important regulatory approvals and positive Phase III readouts (LIPFENDRA approval, sac-TMT, tulisokibart induction, islatravir combos), and raised/narrowed revenue guidance. Offsetting these positives are material one-time charges from the Terns acquisition that produced a GAAP loss and drove a volatile tax rate, margin and expense pressure, one clinical setback (SSc-ILD), and some near-term commercial headwinds (OHTUVAYRE unwind, moderating KEYTRUDA U.S. growth). Overall, management emphasized pipeline derisking, continued launches, and long-term opportunity, while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.View all MRK earnings summariesMRK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
MRK Stock 12 Month Forecast
Average Price Target
$159.76
▲(2.12% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.80% Mutual Funds
1.45% Other Institutional Investors
51.21% Public Companies and Individual Investors